Aimmune Therapeutics

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Aimmune Therapeutics balance sheet

Report period2015 2016 2017 2018 2019 Q2 20
End date of the reporting period
Capitalization, $
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Assets
Total ordinary shares
Ordinary share price

Aimmune Therapeutics cash flows

Report period2015 2016 2017 2018 2019 Q2 20 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Aimmune Therapeutics multipliers

Report period2015 2016 2017 2018 2019 Q2 20 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Net Debt/EBITDA
EV/EBITDA

Aimmune Therapeutics profitability

Report period2015 2016 2017 2018 2019 Q2 20 TTM
ROA
ROE
ROS
Aimmune Therapeutics assets
Aimmune Therapeutics cash flows
Aimmune Therapeutics news
31.08.2020
Nestlé buys Aimmune Therapeutics for $2.6 billion or $34.50 per share. The deal is expected to be closed in Q4 2020.
Source: {source} pictogram ir.aimmune.com
Pictogram next
31.07.2020
The loss of Aimmune Therapeutics under GAAP in 6 months. 2020 was $155.676 million, up 32.9% from $117.144 million in the previous year. Revenue amounted to $0.575 mln. In 1H2019, the company did not receive any revenue.
Source: {source} pictogram ir.aimmune.com
Pictogram next
All Aimmune Therapeutics news
General information
Company nameAimmune Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Mailing address8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Websitewww.aimmune.com
Information disclosurewww.sec.gov